Know Cancer

forgot password

A Phase I Study of Oral Palifosfamide Tris in Advanced, Refractory, Solid Tumors

Phase 1
18 Years
Not Enrolling
Advanced Cancer

Thank you

Trial Information

A Phase I Study of Oral Palifosfamide Tris in Advanced, Refractory, Solid Tumors

Inclusion Criteria:

1. Subjects with histological or cytological confirmation of advanced cancer that is
refractory to standard therapies for their condition.

2. Men and women of ≥18 years of age.

3. Life expectancy of at least 12 weeks.

4. Eastern Cooperative Oncology Group (ECOG) performance score ≤2 (see Appendix 4).

5. Eligible subjects MUST have at least one measurable lesion as defined by RECIST
guidelines. If the measurable disease is restricted to a solitary lesion, its
neoplastic nature should be confirmed by cytology/histology. Measurable lesions must
NOT have been in a previously irradiated field or injected with biological agents.

6. Adequate bone marrow, liver and renal function as assessed by the following
laboratory requirements, to be conducted ≤2 weeks prior to Baseline:

- Creatinine < 1.5× upper limit of normal (ULN) OR a calculated creatinine
clearance ≥70 cc/min

- Total bilirubin ≤2×ULN

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3×ULN

- Granulocytes in peripheral blood ≥2.0×109/L, hemoglobin ≥8.5 g/dL, and platelets

7. Written informed consent in compliance with ZIOPHARM policies and the Human
Investigation Review Committee (IEC/IRB) having jurisdiction over the site.

8. Men and women of childbearing potential must use effective contraception from
Screening through his/her duration of study participation.

9. Women of childbearing potential must have a negative serum pregnancy test prior to
entering the study.

Exclusion Criteria:

1. New York Heart Association (NYHA) functional Class ≥III myocardial infarction (see
Appendix 5) within 6 months.

2. Uncontrolled cardiac arrhythmia other than asymptomatic atrial fibrillation; a QTc
≥450 msec; or a ≥Grade 2 atrioventricular (AV) block or left bundle branch block
(LBBB); or documented history of prolonged QTc.

3. Pregnancy and/or lactation.

4. Uncontrolled systemic infection (documented with microbiological studies).

5. Inadequate renal function as defined by the presence of one or more of the following:

- Creatinine clearance (CrCl) <70 cc/min

- Serum creatinine >1.5×ULN

- Prior nephrectomy

- Urinary tract obstruction

6. Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of study
entry (mitomycin C or nitrosureas should not be given within 6 weeks of study entry).

7. Radiotherapy during study or within 3 weeks of study entry.

8. Surgery within 4 weeks of start of study drug.

9. Other investigational drug therapy outside of this trial during or within 4 weeks of
study entry.

10. History of invasive second primary malignancy diagnosed within the previous 3 years
except for Stage I endometrial/cervical carcinoma or prostate carcinoma treated
surgically, and non-melanoma skin cancer.

11. Substance abuse, medical, psychological, or social conditions that may interfere with
the subject's participation in the study or evaluation of study results.

12. Any condition that is unstable or could jeopardize the safety of the subject and
his/her compliance in the study.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:


Outcome Time Frame:

9 months

Safety Issue:


Principal Investigator

Sachin Shah, MD

Investigator Role:

Study Director

Investigator Affiliation:

ZIOPHARM Oncology, Inc.


United States: Food and Drug Administration

Study ID:




Start Date:

March 2008

Completion Date:

November 2009

Related Keywords:

  • Advanced Cancer
  • Neoplasms